Navigation Links
Testing Lung Cancer Patients for Gene May Aid Treatment, Study Finds
Date:4/22/2013

By Maureen Salamon
HealthDay Reporter

MONDAY, April 22 (HealthDay News) -- Lung cancer patients carrying a rare gene mutation may experience delayed disease progression with drugs often taken by those with breast cancer, a new study suggests.

European researchers found that patients with non-small cell lung cancer who took drugs targeting so-called HER2 proteins -- which result from gene mutations in less than 5 percent of lung cancers -- experienced an extra five months of progression-free survival.

"We were favorably surprised by the outcome of patients and the promising activity of drugs that are usually dedicated to breast cancer patients," said study author Dr. Julien Mazieres, a professor of pulmonology at Larrey Hospital in Toulouse, France. "We do think that all lung [cancers] should be tested for HER2 as is done in France."

The study was published April 22 in the Journal of Clinical Oncology.

Non-small cell is the most common type of lung cancer -- the type seen in about 85 percent of lung cancer cases, according to the American Cancer Society. More than 200,000 Americans are diagnosed with lung cancer each year and 158,000 die from it, according to the U.S. Centers for Disease Control and Prevention.

HER2-positive cancer tests positive for a protein called human epidermal growth factor receptor 2, which feeds the growth of cancer cells and is caused by a gene mutation.

Mazieres and his colleagues identified this mutation in 65 non-small cell lung cancer patients, administering anti-HER2 drugs such as Herceptin (trastuzumab), which also is used to target HER2 in breast cancer patients.

Half of the patients were already at stage 4 lung cancer when diagnosed, while others were at earlier stages of the disease. Notably, most participants with the gene mutation were women, more than half of whom had never smoked.

The extra five months of progression-free survival experienced by patients undergoing HER2 therapies "is a big deal in the cancer business," said Dr. Norman Edelman, chief medical officer of the American Lung Association.

"It's not absolutely a new finding, but it's another study in what is a very exciting field now in cancer," Edelman said. "Up until now, we've treated cancers ... using an elephant gun. This new field looks at the genetic makeup of individual tumors to see if we can attack them in a specific way, not a general way."

Although only a small percentage of lung cancer patients carry this gene mutation, Edelman recommended that all patients be tested for it.

"It's useful and it's being done," he said. "If I had somebody I cared about who I thought had lung cancer, I would say to only go to a center where they're doing this testing. The odds are strong they will not be benefited [by anti-HER2 drugs], but lung cancer is a devastating disease."

Mazieres and Edelman agreed that future research in this area should focus on large clinical trials, which are costly but can tease out various genetic abnormalities that are important to tumor growth.

More information

The U.S. National Library of Medicine has more about lung cancer.

SOURCES: Julien Mazieres, M.D., Ph.D., professor, pulmonology, Larrey Hospital, Toulouse, France; Norman Edelman, M.D., chief medical officer, American Lung Association; April 22, 2013, Journal of Clinical Oncology


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Austin Web Design Firm Fahrenheit Marketing to Launch Qwestrix Loyalty Program in Beta Testing
2. Improved molecular tools streamline influenza testing and management
3. Request A Test is Now Offering More Choices for Magnesium Testing
4. Personalizing prostate specific antigen testing may improve specificity, reduce biopsies
5. The Gluten Free Society Launches Gluten Sensitivity and Celiac Disease At-Home Testing
6. DISC Personality Testing in the Workplace by PeopleKeys: A New Strategy for Building Successful Teams
7. Oregon Canna-Businesses Take One Small Step For Dispensaries, One Giant Leap For Testing Labs
8. Advances in molecular testing offer new hope for lung cancer patients
9. HIV self-testing: The key to controlling the global epidemic
10. Could Self-Testing Help Overcome HIV/AIDS Epidemic?
11. Request A Test Offers 10% off STD testing in April 2013
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Testing Lung Cancer Patients for Gene May Aid Treatment, Study Finds
(Date:1/18/2017)... ... January 18, 2017 , ... ... that their Vice President of Franchise Development, Paula Turner Pizarro, was recently featured ... program, which features the insights of top business leaders from across the globe, ...
(Date:1/18/2017)... ... January 18, 2017 , ... At Hallmark Nameplate, their commitment to quality ... achieved certification to ISO 13485. This certification is another way they are making constant ... and services that they need. , The ISO 13485 Certification is a major accomplishment ...
(Date:1/18/2017)... ... January 18, 2017 , ... Michael J. Hennessy ... for its Center for Biosimilars, announced Michael J. Hennessy Associates, Inc. President Michael ... field of biosimilars through thought leader interaction in, live video and interactive digital ...
(Date:1/18/2017)... ... January 18, 2017 , ... During pregnancy, ... to enamel erosion, and those dental problems can increase the risk of pregnancy ... pregnant women are failing to get the dental care they need. Agoura Hills ...
(Date:1/17/2017)... ... ... Anesthesia Progress – Everyone wants less pain during dental surgery, ... each patient. Dentists have several general anesthesia alternatives and finding the right option can ... Dental College in Tokyo, Japan wanted to find out which anesthetic was the better ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... YORK , Jan. 17, 2017 EU5 ... GlobalData,s new report, "EU5 Glucose Monitoring Market Outlook ... Glucose Monitoring market. The report provides value, in millions ... (USD) within market segments - Blood Glucose Meters, Blood ... provides company shares and distribution shares data for each ...
(Date:1/17/2017)... 17, 2017 Paragon Bioservices received a multiple-award, ... services for a variety of National Institute ... product development activities. The IDIQ mechanism will allow ... task order awards up to $159 million. ... and process development of biopharmaceuticals, is one of ...
(Date:1/17/2017)... Pa. , Jan. 17, 2017  Pennsylvania ... today announced applications for medical marijuana growers/processors and ... Medical Marijuana Program website . Permit applications will ... 2017. "This is an important step ... who desperately need it," Secretary Murphy said. "We,ve ...
Breaking Medicine Technology: